RANKL antibody (Center)
Quick Overview for RANKL antibody (Center) (ABIN500805)
Target
See all RANKL (TNFSF11) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- Center
-
Specificity
- This antibody detects CD254 / RANKL. It will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.
-
Cross-Reactivity (Details)
- Species reactivity (tested):Human, Mouse and Rat.
-
Purification
- Immunoaffinity Chromatography
-
Immunogen
- sRANK-L antibody was raised against a 14 amino acid peptide from near the center of Human sRANK-L.
-
Isotype
- IgG
-
-
-
-
Application Notes
-
ELISA. Western blot: 0.25 - 0.5 μg/mL. Immunohistochemistry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- PBS, 0.02 % Sodium Azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
-
: "Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain." in: Mediators of inflammation, Vol. 2019, pp. 2514956, (2019) (PubMed).
: "The role of mechanotransduction versus hypoxia during simulated orthodontic compressive strain-an in vitro study of human periodontal ligament fibroblasts." in: International journal of oral science, Vol. 11, Issue 4, pp. 33, (2019) (PubMed).
-
-
- RANKL (TNFSF11) (Tumor Necrosis Factor (Ligand) Superfamily, Member 11 (TNFSF11))
-
Alternative Name
- CD254 / RANKL
-
Background
- The receptor activator of NF-kappaB ligand (RANK-L) is a recently discovered member of the TNF-ligand family involved in the regulation of the T cell-dependent immune response, lymph node organogenesis and bone formation. RANK-L exists as both a normal, transmembrane form and a truncated, soluble form (sRANK-L), both of which can stimulate the receptor. Activation of T cells, such as by treatment with interleukin-7, induces RANK-L production and leads to an increase of osteoclast formation and bone loss. Finally, sRANK-L can activate the antiapoptotic kinase Akt through a signaling complex involving Src kinase and TRAF6, suggesting sRANK-L may also play a role in regulating apoptosis.Synonyms: ODF, OPGL, Osteoclast differentiation factor, Osteoprotegerin ligand, RANK Ligand, RANKL, Receptor activator of nuclear factor kappa B ligand, TNF-related activation-induced cytokine, TNFSF11, TRANCE, Tumor necrosis factor ligand superfamily member 11
-
Gene ID
- 8600
-
NCBI Accession
- NP_003692
-
Pathways
- NF-kappaB Signaling
Target
-